AU Patent

AU2021358394A1 — Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma

Assigned to Pierre Fabre Medicament SA · Expires 2023-04-13 · 3y expired

What this patent protects

The present invention relates to a pharmaceutical combination for use as adjuvant treatment after resection of a melanoma, wherein the melanoma which has been resected is stage II melanoma, and wherein the pharmaceutical combination comprises therapeutically effective amounts, in…

USPTO Abstract

The present invention relates to a pharmaceutical combination for use as adjuvant treatment after resection of a melanoma, wherein the melanoma which has been resected is stage II melanoma, and wherein the pharmaceutical combination comprises therapeutically effective amounts, independently, of: a) encorafenib or a pharmaceutically acceptable salt thereof; b) binimetinib or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021358394A1
Jurisdiction
AU
Classification
—
Expires
2023-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Pierre Fabre Medicament SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.